MBOT
NASDAQMicrobot Medical Inc.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
Price$1.50-0.29 (-16.48%)
2026-05-212026-08-25
News · 26 weeks580%
2026-03-012026-08-23
Mix2090d
- SEC Filings11(55%)
- Other8(40%)
- Leadership1(5%)
Latest news
25 items- SECMicrobot Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Microbot Medical Inc. (0000883975) (Filer)
- PRMicrobot Medical® Files 10-Q, Reports Significant Revenue and Customer Growth During the 2026 Second QuarterRevenue increased by more than 100% over the prior fiscal quarter, driven by repeat orders, expanded utilization among existing customers, and the acquisition of new customers since the Full Market Release in mid-April The Company added new customers in Q3 while expanding into new states and sites of service HINGHAM, Mass., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2026 with the Securities and Exchange Commission (SEC). As disclosed in its July 7, 2026 press release, the Compa
- SECSEC Form 10-Q filed by Microbot Medical Inc.10-Q - Microbot Medical Inc. (0000883975) (Filer)
- SECMicrobot Medical Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Financial Statements and Exhibits8-K - Microbot Medical Inc. (0000883975) (Filer)
- SECMicrobot Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Microbot Medical Inc. (0000883975) (Filer)
- PRMicrobot Medical® Among Featured Companies Showcasing Novel Robotic Technologies and Digital Surgery Applications at the Society of Robotic Surgery Annual MeetingHINGHAM, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, will be participating at this year’s Society of Robotic Surgery (SRS) annual meeting, being held from July 23-26, in Fort Lauderdale, FL. Last year’s meeting was the first time that endovascular robotics was featured at SRS, and with the Company’s FDA clearance less than a year ago and the growing adoption of the LIBERTY System at leading academic centers in the U.S. for a broad range of peripheral endovascular procedures, the Company believes the continued focus on this segment of the market underscores its increasing impo
- SECMicrobot Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Microbot Medical Inc. (0000883975) (Filer)
- PRMicrobot Medical® Reports Over 100% Revenue and Customer Growth as Procedure Volume Also Rises in the Second Quarter of 2026The Company is experiencing rising demand and increasing pipeline for the LIBERTY System since commencing the Full Market Release in April Heightened awareness generating interest from leading health systems across the U.S. as Company plans to increase its U.S. sales territories from 8 to 12 and enter international markets by the end of 2026 HINGHAM, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, is reporting greater than 100% growth in revenue and new customers for the second quarter ended June 30, 2026, compared to the first quarter ended March 31, 2026. The performance ref
- SECMicrobot Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Microbot Medical Inc. (0000883975) (Filer)
- PRMicrobot Medical® Increases Manufacturing Capacity as Demand for the LIBERTY® System Rises; Enters into Strategic Agreement with Sanmina, a Global Manufacturing LeaderHINGHAM, Mass., June 30, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, has entered into a Letter of Agreement (LOA) with Sanmina Corporation, a leading global integrated manufacturing solutions provider, to manufacture the LIBERTY System, the only FDA-cleared single-use, remotely operated robotic system for peripheral endovascular procedures. As momentum continues to rise in the U.S., reflected in increased accounts and usage across several states, and with the momentum building in the international markets as seen with the recent clearance in Israel and progress towards obtaining CE Mark as w
- SECMicrobot Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Microbot Medical Inc. (0000883975) (Filer)
- PRMicrobot Medical® Wins Surgical Robotics Industry Award for the LIBERTY® Endovascular Robotic SystemHINGHAM, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it has won the Innovative Start-Up Award from Surgical Robotics Technology (SRT), which recognizes companies with outstanding technological and commercial progress through highly innovative, groundbreaking technologies with the potential for broad healthcare impact.1 SRT, a leading platform for surgical robotics news, together with QNX, recognizes outstanding organizations, individuals, and technologies across the surgical robotics sector. LIBERTY is the only FDA-cleared, single-use, remotely operated roboti
- SECMicrobot Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Microbot Medical Inc. (0000883975) (Filer)
- PRMicrobot Medical® Announces First Health System in Pennsylvania to Adopt the LIBERTY® Endovascular Robotic SystemLeading academic center with multi-hospital and multi-state health system deepens Company’s footprint in the Northeast U.S. The Company now has multiple accounts and hospitals that have adopted the LIBERTY System across seven states in the U.S. HINGHAM, Mass., June 23, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that a globally recognized academic center headquartered in Pennsylvania is the first in the state to adopt the LIBERTY System, allowing the Company to further expand its presence in the Northeast U.S., joining other health systems in New York City and Boston that have al
- SECMicrobot Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Microbot Medical Inc. (0000883975) (Filer)
- PRMicrobot Medical® Enters Into an Agreement to Expand Access for America's Veteran and Military Patient PopulationsHINGHAM, Mass., June 16, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, has entered into an agreement with Lovell® Government Services to serve federal healthcare systems, such as those administered by the Veterans Health Administration (VHA), a division of the U.S. Department of Veteran Affairs, the Military Health System (MHS), which is run by the U.S. Department of Defense, and the U.S. Indian Health Service (IHS). Lovell Government Services will become Company's Service-Disabled Veteran-Owned Small Business (SDVOSB) vendor to serve these customers through federal contracting systems. Lovel
- SECMicrobot Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Microbot Medical Inc. (0000883975) (Filer)
- PRMicrobot Medical® Announces a Notable Health System as the First in Michigan to Adopt the LIBERTY® Endovascular Robotic SystemHINGHAM, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that one of the largest healthcare systems in Michigan is the first health network in Michigan and across the greater Midwest U.S. to adopt the LIBERTY System. This adoption follows the Company's recent announcement of its first healthcare system customer in North Carolina, further expanding LIBERTY's presence across multiple strategic U.S. regions and reinforcing growing interest among health systems. The Company believes the ongoing progress across new and existing sales territories reflects growing demand for
- SECMicrobot Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Microbot Medical Inc. (0000883975) (Filer)
- PRMicrobot Medical® Secures the First Healthcare System in North Carolina to Adopt the LIBERTY® Endovascular Robotic SystemHINGHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it has secured its first North Carolina-based customer, becoming the latest healthcare system to adopt the LIBERTY System, demonstrating a broadening geographic penetration from the Southeast, Mid-Atlantic and Northeast U.S. The Company's latest account delivers state of the art patient care through a multi-hospital network that encompasses the entire state and joins a growing roster of health systems that we believe recognize the unique benefits of the LIBERTY system. "It's exciting to see the pace of incre
- PRMicrobot Medical® Receives Its First International Regulatory Approval for the Commercialization of the LIBERTY® Endovascular Robotic SystemIsrael becomes the second jurisdiction and the first outside of the U.S. to grant marketing clearance for the LIBERTY System The AMAR regulatory approval will enable the Company to obtain a Free Sale Certificate to support submissions and commercial activities in additional jurisdictions HINGHAM, Mass.,, May 26, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it has achieved a significant regulatory milestone as Israel becomes the second jurisdiction — and the first outside of the U.S. — to grant marketing clearance for the LIBERTY System. The regulatory approval from the Israe
- SECMicrobot Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Microbot Medical Inc. (0000883975) (Filer)
- SECMicrobot Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Microbot Medical Inc. (0000883975) (Filer)
- PRMicrobot Medical to Hold Analysts and Investors Conference Call to Review Recent Progress; Executive Team will be Joined by Current Users of the LIBERTY Endovascular Robotic System, Dr. Charles Briggs and Dr. Zachary BercuConference call and live webcast to be held Monday, May 18th at 3:00pm ET Wall Street firm publishes research report refuting claims made by recent unaffiliated third-party article; Research report also references Vascular Surgeon who categorically disputes many of the assertions that were attributed to him in same unaffiliated third-party article Company to review claims made in the unaffiliated third-party article, to correct certain misleading statements and misrepresentations to ensure the investing public is fully informed of the actual facts HINGHAM, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY® E
- SECMicrobot Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Microbot Medical Inc. (0000883975) (Filer)
MBOT FAQ
6 questionsWhat does Microbot Medical Inc. do?
Microbot Medical Inc., a pre-clinical medical device company, researches, designs, and develops micro-robotics assisted medical technologies targeting the minimally invasive surgery space. The company, through its ViRob, TipCAT, and Liberty micro-robotic technologies, developing Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; a disposable self-propelled locomotive device to treat capabilities within tubular lumens, such as the blood vessels, respiratory, and the urinary and GI tracts; a combination of a guidewire and microcatheter technologies that...Where does MBOT stock trade?
Microbot Medical Inc. (MBOT) is listed on NASDAQ.What sector and industry is MBOT in?
Microbot Medical Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What are analysts saying about MBOT?
Microbot Medical Inc. has had 2 recent analyst actions on file. The most recent action was from B. Riley Securities: Buy with a $500.00 price target on 2026-02-10. Recent price targets range from $500.00 to $550.00.What companies are similar to MBOT?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare MBOT side-by-side with any of them on Quantisnow.How can I track MBOT on Quantisnow?
Quantisnow aggregates Microbot Medical Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MBOT to receive live email and push alerts on every new disclosure.